Physician profile
Daniel P Sporn
NPI 1871568923
$1,652.55
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $134 · 2021: $122 · 2022: $183 · 2023: $223 · 2024: $559 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $292.62 | 2019-2025 | Amvia Edge, Biomonitor, Acticor 7 Vr-T Dx |
| Medtronic, INC. | $287.20 | 2021-2024 | Corevalve Evolut R |
| Pfizer INC. | $224.58 | 2019-2023 | |
| Abiomed | $180.13 | 2024 | Impella |
| Inari Medical, INC. | $141.66 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $136.96 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $132.48 | 2020-2021 | |
| Abbott Laboratories | $99.19 | 2024-2025 | Optis, Mitraclip, Dragonfly Opstar |
| Lexicon Pharmaceuticals, INC. | $57.85 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $43.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $16.45 | 2019 | |
| Novo Nordisk INC | $14.52 | 2024 | Ozempic, Rybelsus |
| Bardy Diagnostics, INC. | $13.00 | 2021 | |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sporn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.